The regulation of peripheral metabolism by gut-derived hormones
Brunswick is a service area, not a branch
The KLOTHO Birth Cohort: Maternal and Neonatal Vitamin D Status and Neurodevelopmental Outcomes at 10 Years
The shortages have caused the company to expand and build new production facilities to meet the demand for Saxenda and other GLP-1 products
Many insurance plans require documentation of 3 months of a physician-supervised weight loss program before they agree to pay for Saxenda. On average, Victoza is typically less expensive than Saxenda, although both drugs can still cost over $1,000/month for patients who are paying completely out of pocket
Novo Nordisk leads the sector in spending on shareholder enrichment: With a ratio of 1.41, Novo Nordisk spent 41% more on shareholder returns (buybacks and dividends) compared to R&D, making it the highest spender on shareholder enrichment among 15 peer companies 9 in the pharmaceutical sector